{"nctId":"NCT05395091","briefTitle":"Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND","startDateStruct":{"date":"2022-08-23","type":"ACTUAL"},"conditions":["Osteoporosis, Postmenopausal"],"count":532,"armGroups":[{"label":"AVT03","type":"EXPERIMENTAL","interventionNames":["Biological: AVT03"]},{"label":"Prolia","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Denosumab"]}],"interventions":[{"name":"AVT03","otherNames":[]},{"name":"Denosumab","otherNames":["Prolia"]}],"eligibilityModule":{"eligibilityCriteria":"1. Postmenopausal women with osteoporosis willing to sign an informed consent form (ICF)and able to undergo protocol related procedures.\n2. A baseline dual-energy x-ray absorptiometry (DXA) scan with a T score ≤-2.5 and\n\n   * 4.0 at the LS (L1 to L4)and/or, total hip, and/or femoral neck.\n3. Age: ≥50 years.\n4. Female subject is postmenopausal according to 1 of the following criteria:\n\n   1. Spontaneous amenorrhea for ≥12 consecutive months\n   2. Biochemical criteria of menopause, follicle-stimulating hormone, \\>40 IU/L except surgically sterile\n   3. Having had bilateral oophorectomy ≥6 weeks prior to Screening\n5. Willing to receive calcium plus vitamin D supplements.\n6. At least 2 consecutive evaluable lumbar vertebrae and at least 1 evaluable hip.\n\nExclusion Criteria\n\n1. Evidence of clinically relevant pathology, especially prior diagnosis of bone disease, or any uncontrolled condition that will affect bone metabolism\n2. History and/or presence of 1 severe or more than 1 moderate vertebral fractures confirmed by x-ray.\n3. History of hip fracture\n4. Presence of active healing fractures\n5. Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures\n6. Evidence of hypo/hypercalcemia at Screening\n7. Known vitamin D deficiency\n8. Known intolerance to calcium and vitamin D supplement.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®.","description":"Percent Change From Baseline in LS BMD at Month 12 to demonstrate comparable efficacy of AVT03 and Prolia®.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"0.870"},{"groupId":"OG001","value":"5.18","spread":"0.872"}]}]}]},{"type":"PRIMARY","title":"To Demonstrate Comparable Profile of AVT03 and Prolia in Terms of Area Under the Percent Change From Baseline in Serum C-telopeptide of Type 1 Collagen (AUEC of %Cfb sCTX-1)","description":null,"paramType":"GEOMETRIC_LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2345.55","spread":"1.011"},{"groupId":"OG001","value":"2342.87","spread":"1.011"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LS BMD","description":"Percent change from Baseline in LS BMD at 6 and 18 months","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percent Change From Baseline in Hip and Femoral Neck BMD","description":"Percent change from Baseline in hip and femoral neck BMD at Month 6, 12 and 18 months","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of New Morphometric Vertebral Fractures","description":"Incidence of new morphometric vertebral fractures at 12 and 18 months","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Percent Change From Baseline in sCTX-1","description":"Percent change from Baseline in sCTX-1 at 3, 6, 9, 12 and 18 months","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence, Nature and Severity of Adverse Events Including Adverse Drug Reactions","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Frequency and Severity of Injection Site Reactions","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Frequency and Severity of Findings in Routine Safety Parameters","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Frequency and Titer of Anti-drug Antibodies and Frequency of Neutralizing Antibodies Against AVT03 and Prolia","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Serum Trough Concentration of AVT03 and Prolia","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":266},"commonTop":["Upper respiratory tract infection","Hypocalcaemia","Nasopharyngitis","Activated partial thromboplastin time prolonged","Adjusted calcium decreased"]}}}